Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,945 signal articles · 241 in last 24h · 118,911 total before filter · latest 28m ago
241last 24h
1545last 7d
256● bullish (7d)
160● bearish (7d)
205publishers
AllMacro299Earnings620M&A104Regulatory22Product14Analyst22
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Berkshire’s Bigger Bet on Delta (DAL) Altering The Investment Case For The Airline?
Simply Wall St.3d agoneutral
Is Berkshire’s Bigger Bet on Delta (DAL) Altering The Investment Case For The Airline?

In recent filings, Berkshire Hathaway disclosed that it added millions of Delta Air Lines shares while also reshaping its broader equity portfolio, including exiting Constellation Brands and trimming its Bank of America stake. This increased exposure places Delta alongside Berkshire’s core holdings such as Apple, American Express, Alphabet, Coca-Cola, and Bank of America, highlighting the airline’s importance within a highly concentrated investment lineup. Now, we’ll examine how Berkshire’s...

Is Pony AI (PONY) Undervalued Following Its Uber Robotaxi Expansion Plan?
Simply Wall St.3d agoneutral
Is Pony AI (PONY) Undervalued Following Its Uber Robotaxi Expansion Plan?

Pony AI (PONY) stock is in focus after the company and Uber announced plans to deploy more than 2,000 Pony.ai Robotaxis across Europe, with additional expansion planned in the Middle East. See our latest analysis for Pony AI. The Uber partnership headlines come after a sharp reset in Pony AI’s performance this year. The share price is at US$8.14 and the year-to-date share price return is down 49.35%, despite a 13.85% one-month share price rebound. The one-year total shareholder return is down...

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity
Insider Monkey3d agobullish
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial results from its drug candidate for hot flashes in menopausal women. On Friday alone, the stock climbed to its highest price in three years of […]

3 Industrials Stocks Walking a Fine Line
StockStory3d agoneutral
3 Industrials Stocks Walking a Fine Line

Industrials businesses quietly power the physical things we depend on, from cars and homes to e-commerce infrastructure. But they are at the whim of volatile macroeconomic factors that influence capital spending (like interest rates), and the industry has underperformed the market over the past six months as its 2.1% return lagged the S&P 500 by 10.9 percentage points.

Morgan Stanley sends a blunt Tesla message to investors
TheStreet3d agoneutral
Morgan Stanley sends a blunt Tesla message to investors

The spending is going up. The margins are going down. Free cash flow is negative. And a Wall Street analyst who covers one of the most closely watched stocks in the market just published a note saying the next quarter has to be different. The note comes from Morgan Stanley. The company it covers is ...

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
MarketBeat3d agoneutral
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar

1 S&P 500 Stock Worth Investigating and 2 We Turn Down
StockStory3d agoneutral
1 S&P 500 Stock Worth Investigating and 2 We Turn Down

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Delta Air Lines (DAL) Stock Looks Undervalued While Broader Checks Stay Mixed
Simply Wall St.3d agoneutral
Delta Air Lines (DAL) Stock Looks Undervalued While Broader Checks Stay Mixed

Delta Air Lines stock has delivered a strong 142.8% return over the past 5 years, yet current valuation checks point to a mixed picture rather than a clear bargain or clear overvaluation. Over 5 years, Delta Air Lines shares are up 142.8%, which means anyone looking at the stock today is assessing it after a substantial multi year gain. The profit gap that competitors like American Airlines are trying to close highlights Delta Air Lines' earnings strength, although any shift in industry...

QXO (QXO) Stock May Be A Bargain As An $86 Million Verdict Looms
Simply Wall St.3d agoneutral
QXO (QXO) Stock May Be A Bargain As An $86 Million Verdict Looms

QXO stock has had a tough run over the last few years, yet the current market multiples still screen the shares as undervalued while the broader valuation checks give a more cautious read. That mix leaves investors weighing weak long term returns against indications that the price may already build in a fair amount of bad news. QXO has declined 69.6% over the past 5 years, which suggests sentiment has been weak for an extended period and expectations have reset lower. Legal risk is front of...

Apple’s first foldable could reshape its entire iPhone launch
TheStreet3d agoneutral
Apple’s first foldable could reshape its entire iPhone launch

Apple (AAPL) will allegedly focus on producing and shipping its three most high-end 2026 models and defer the regular iPhone 18 to the first half of 2027 rather than releasing all new iPhone models at the same time. But if the scheme works, it would disclose something big about Apple's intentions. ...

Investing.com3d agoneutral
How could open-weight models impact GenAI ROIC?

Investing.com -- The rise of lower-cost open-weight AI models could pressure pricing and returns for model developers, but hyperscalers should continue generating attractive returns from the computing infrastructure needed to run them, Morgan Stanley analysts said.

1 Growth Stock to Stash and 2 We Brush Off
StockStory3d agoneutral
1 Growth Stock to Stash and 2 We Brush Off

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

3 Reasons to Sell ROCK and 1 Stock to Buy Instead
StockStory3d agoneutral
3 Reasons to Sell ROCK and 1 Stock to Buy Instead

Over the past six months, Gibraltar’s stock price fell to $49.10. Shareholders have lost 10.3% of their capital, which is disappointing considering the S&P 500 has climbed by 13%. This may have investors wondering how to approach the situation.

3 Reasons to Avoid CCL and 1 Stock to Buy Instead
StockStory3d agobullish
3 Reasons to Avoid CCL and 1 Stock to Buy Instead

Over the past six months, Carnival’s stock price fell to $27.70. Shareholders have lost 12.8% of their capital, which is disappointing considering the S&P 500 has climbed by 13%. This may have investors wondering how to approach the situation.

Block’s (XYZ) EPS Surged 65%, So Why Did the Stock Drop?
Insider Monkey3d agoneutral
Block’s (XYZ) EPS Surged 65%, So Why Did the Stock Drop?

Block Inc. (NYSE:XYZ) posted one of its strongest quarters in years on August 5, then watched its shares fall roughly 6% the next day. Adjusted EPS came in at $1.02, well ahead of the $0.87 Wall Street expected, and the company raised its full-year guidance across the board. Investors, it turns out, cared more about […]